Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model

Blood Cancer Journal

Volumn 3, Issue 3, 2013, Pages

  Schiffer, S ^a,b   Hansen, H P ^c   Hehmann Titt, G ^d   Huhn, M ^a   Fischer, R ^b   Barth, S ^a,b   Thepen, T ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d PharmedArtis GmbH   (Germany)

Author keywords

Immunotoxin; Serine Protease; Serpin B9; Targeted Cancer Therapy; Treatment Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; GB KI4 FUSION PROTEIN; GBK27A KI4 FUSION PROTEIN; GBR201A KI4 FUSION PROTEIN; GBR201K KI4 FUSION PROTEIN; GBR28K KI4 FUSION PROTEIN; GRANZYME B; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLASSICAL HODGKIN LYMPHOMA; FLUORESCENCE IMAGING; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL LINE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN;

EID: 84878342444     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.4     Document Type: Article

References (34)

1. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100: 1359-1365.
2. Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH et al. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol 2011; 68: 979-990.
3. Kurschus FC, Fellows E, Stegmann E, Jenne DE. Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci USA 2008; 105: 13799-13804.
4. Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010; 235: 159-171.
5. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2003; 2: 1341-1350.
6. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7: 2924-2932.
7. Zhang L, Zhao J, Wang T, Yu CJ, Jia LT, Duan YY et al. HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol Ther 2008; 7: 1226-1231.
8. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z et al. Secreted antibody/ granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004; 279: 21343-21348. (Pubitemid 38656542)
9. Andrade F, Casciola-Rosen LA, Rosen A. Granzyme B-induced cell death. Acta Haematol 2004; 111: 28-41. (Pubitemid 37499953)
10. Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC. Granulemediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006; 17: 623-633. (Pubitemid 43191098)
11. Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007; 26: 4106-4114. (Pubitemid 46920175)
12. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11: 6400-6407. (Pubitemid 41262972)
13. Soriano C, Mukaro V, Hodge G, Ahern J, Holmes M, Jersmann H et al. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: Mechanism for immune evasion? Lung Cancer 2012; 77: 38-45.
14. Ray M, Hostetter DR, Loeb CR, Simko J, Craik CS. Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis. Prostate 2012; 72: 846-855.
15. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: A novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232-237.
16. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-4546. (Pubitemid 34627225)
17. Losasso V, Schiffer S, Barth S, Carloni P. Design of human granzyme B variants resistant to serpin B9. Proteins 2012; 80: 2514-2522.
18. Pardo A, Stocker M, Kampmeier F, Melmer G, Fischer R, Thepen T et al. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 2012; 61: 1617-1626.
19. Sun J, Whisstock JC, Harriott P, Walker B, Novak A, Thompson PE et al. Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. J Biol Chem 2001; 276: 15177-15184.
20. Stocker M, Pardo A, Hetzel C, Reutelingsperger C, Fischer R, Barth S. Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expr Purif 2008; 58: 325-331.
21. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909-3914. (Pubitemid 30412867)
22. Edwards KM, Davis JE, Browne KA, Sutton VR, Trapani JA. Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immuno Cell Biol 1999; 77: 76-89. (Pubitemid 29111594)
23. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer 1992; 52: 887-891. (Pubitemid 23009504)
24. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stocker M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 31: 370-376. (Pubitemid 351595159)
25. Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R et al. Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nuc Med Mol Imaging 2010; 37: 1926-1934.
26. Klimka A, Matthey B, Roovers RC, Barth S, Arends JW, Engert A et al. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Br J Cancer 2000; 83: 252-260. (Pubitemid 30411726)
27. Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP et al. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 2004; 18: 893-895.
28. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
29. Mahrus S, Kisiel W, Craik CS. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 2004; 279: 54275-54282. (Pubitemid 40053165)
30. Classen CF, Bird PI, Debatin KM. Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol 2006; 143: 534-542.
31. Tiacci E, Doring C, Brune V, van Noesel CJ, Klapper W, Mechtersheimer G et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609-4620.
32. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045-2056. (Pubitemid 24112714)
33. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953. (Pubitemid 29086271)
34. Godal R, Keilholz U, Uharek L, Letsch A, Asemissen AM, Busse A et al. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood 2006; 107: 3205-3211.